NuSynth Technologies, an R&D-led collaborative platform for process innovation in complex chemistry, has successfully raised ₹36.5 crore (about $4 million) in seed funding. According to reports from Economic Times and ETEntrepreneur, the funding round was co-led by Avaana Capital and Shastra VC, positioning the company to expand its research and development capabilities and build AI-enabled scale-up infrastructure. The fresh capital will be used to strengthen its R&D and technology capabilities, develop an initial portfolio of proprietary chemical processes, build scale-up capabilities, and expand its team. As reported by Avaana Capital, the startup will use the funding to strengthen its R&D and technology capabilities, develop an initial portfolio of proprietary chemical processes, build scale-up capabilities, and expand its team.
The company addresses a critical gap in India's chemical manufacturing sector by redesigning chemical processes from first principles rather than making incremental improvements. As reported by Economic Times and ETEntrepreneur, NuSynth re-evaluates starting materials, reaction pathways and process economics to develop synthetic routes that improve cost efficiency, yield, cycle time, safety, sustainability and scalability. According to Avaana Capital, NuSynth's processes seek to reduce reaction steps, eliminate hazardous reagents, lower temperature requirements, and replace solvent-intensive processes with catalytic and water-based alternatives. Each R&D cycle combines first-principles process redesign with predictive synthesis models, incorporating manufacturability, raw-material economics, safety and quality from the outset. The platform uses experimental data to feed its AI engine, building a proprietary knowledge base that accelerates future molecule selection, experimentation and commercial scale-up, shortening traditional R&D gestation cycles. The bet is not on scaling up an existing recipe, but on rewriting it to achieve better yields, lower costs and easier scale-up, especially in sectors where India still depends on imported intermediates and costly reagents.
According to Economic Times and ETEntrepreneur reports, despite significant growth in chemical manufacturing, India still relies on complex, multi-step synthesis routes for many critical molecules, increasing material and energy costs, dependence on imported intermediates and hazardous reagents, and challenges in commercial scale-up. NuSynth begins with high-value sectors such as pharmaceuticals and electronic chemicals, building process innovation capabilities that will extend across multiple chemistry-led sectors over time. The startup is initially targeting pharmaceuticals and electronics chemicals, working with Indian manufacturing partners to take its processes from laboratory validation to industrial production. The company's platform approach is based on the premise that commercially important molecules can be produced through redesigned processes, combining its R&D engine with in-house scientific expertise and collaboration with a network of scientists and entrepreneurs to develop a repeatable approach to originating chemistry and translating it into commercially scalable processes.
The founding team combines expertise in scientific R&D, commercialisation and business building. Poorvank Purohit, former MD and CEO of Solara Active Pharma Sciences, brings industry experience and global customer relationships, while Dr Ramesha A R, a postdoctoral researcher at NIH, Washington, and PhD graduate from IISc, contributes scientific and R&D expertise. Abhishek Deo and Dipak Bajaj bring commercial and operating experience across Zetwerk, Mstack, Ola, JPMorgan, BlackBuck and SUN Mobility, having led multiple zero-to-scale journeys including companies that achieved unicorn scale and public-market milestones. As reported by Economic Times and ETEntrepreneur, Purohit framed the opportunity as the next stage of India's industrial chemistry story, arguing that the country has already proven its strength in established manufacturing and now needs to build originality into the chemistry layer itself. The company's ambition is to build proprietary processes from India that can deliver superior economics and sustainability, and serve customers across global markets. NuSynth follows an asset-light manufacturing model, working with Indian manufacturing partners to translate its laboratory research into industrial-scale production, as reported by Avaana Capital.
Shruti Srivastava, partner at Avaana Capital, believes NuSynth's approach will improve the economics, resource efficiency and resilience of chemical manufacturing across critical sectors, while creating globally competitive technology platforms from India. Avijeet Alagathi, managing partner at Shastra VC, highlighted that the founding team brings together a rare combination of scientific depth, industry experience and execution capability, positioning NuSynth to build a differentiated process innovation platform from India for global markets. Her remarks underline why capital is flowing into deeper-tech chemical platforms rather than only into capacity expansion, with the funding pointing to a larger theme of building originality into India's chemistry layer.
